Panel Backs Insomnia Drug; GSK, U.S. Partner on Antibiotics

May 23 • Uncategorized • 1139 Views • Comments

View Online | Subscribe | Unsubscribe
Facebook Twitter
ddd_calendar_top.jpg
MAY
23
ddd_calendar_bottom.jpg

Drug Discovery & Development Update

IN THIS ISSUE
NEWS
Despite Concerns, Panel Backs Insomnia Drug
ARTICLE
A Potential Treatment for Hypoactive Sexual Desire Disorder
NEWS
J&J Forecasts 10 NDAs by 2017
NEWS
Glaxo, U.S. Partnering on Antibiotics
NEWS
Moody’s Reviewing Hospira Debt Rating
ADVERTISEMENT

Detect & Isotype Anti-Drug Antibodies in One Assay

The Maverick MT-ADA assay streamlines immunogenicity testing by combining screening, confirmatory, and isotyping tiers into a single assay providing real-time detection of anti-drug antibodies.

LEARN MORE ddd_ad_cta_btn_right.png
FEATURED STORY

Despite Concerns, Panel Backs Insomnia Drug

A majority of medical experts on a U.S. Food and Drug Administration panel said that an experimental insomnia drug from Merck & Co. Inc. appears safe and effective, in spite of evidence from company trials that the pill can cause daytime sleepiness and difficulty driving.

Share Facebook Twitter Google+ LinkedIn StumbleUpon
FULL STORY ddd_content_cta_btn_right.png
ADVERTISEMENT

What if you could stop worrying about endotoxin removal?

CleanColi™ competent cells are the first E. coli with a genetically modified LPS that does not cause endotoxic response in human cells.

LEARN MORE ddd_ad_cta_btn_right.png
ARTICLE

A Potential Treatment for Hypoactive Sexual Desire Disorder

Thumbnail

Hypoactive sexual desire disorder affects 10% of women in the United States and significantly higher percentages of women who have undergone surgical menopause.There are no U.S. Food and Drug Administration-approved treatments for this large, unmet medical need.

FULL STORY ddd_content_cta_btn_right.png
NEWS

J&J Forecasts 10 NDAs by 2017

Johnson & Johnson plans to submit more than 10 new treatments to regulators for approval and 25 applications for additional uses of approved drugs by 2017. The company’s pipeline of late-stage drugs include a hepatitis C treatment, a long-lasting version of Invega, and several vaccines.

FULL STORY ddd_content_cta_btn_right.png
ADVERTISEMENT

Mitochondrial Function Screening Products & Services

Screening for mitochondrial RNA Polymerase (POLRMT) toxicity just got easier and more reliable. INDIGO Biosciences, Inc. offers a unique set of products designed to evaluate potential for POLRMT inhibition by anti-viral drugs. Mitochondrial gene expression studies are also available.

LEARN MORE ddd_ad_cta_btn_right.png
NEWS

Glaxo, U.S. Partnering on Antibiotics

GlaxoSmithKline is beginning starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and drug-resistant bacteria. Glaxo’s partnership will bring the British drugmaker $40 million over the first 18 months.

FULL STORY ddd_content_cta_btn_right.png
NEWS

Moody’s Reviewing Hospira Debt Rating

Moody’s Investors Service has placed Hospira Inc.’s long-term debt rating under review for possible downgrade. The move was based on a concern that the company’s performance over the next few years remains uncertain as a result of costs related to its new product strategy and possible regulatory issues.

FULL STORY ddd_content_cta_btn_right.png
Drug Discovery & Development
Facebook Twitter
SUBSCRIBE | UNSUBSCRIBE | ABOUT US | ADVERTISE
This email was sent by: Drug Discovery & Development

100 Enterprise Drive – Suite 600 – Rockaway, NJ 07866-2129

We respect your right to privacy – click here to view our policy.

Thanks for installing the Bottom of every post plugin by Corey Salzano. Contact me if you need custom WordPress plugins or website design.

Related Posts

« »

%d bloggers like this: